Stock MACK MERRIMACK PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Merrimack Pharmaceuticals, Inc.

Equities

MACK

US5903282094

Market Closed - Nasdaq
Other stock markets
 21:00:00 07/05/2024 BST 		5-day change 1st Jan Change
15.04 USD +0.27% Intraday chart for Merrimack Pharmaceuticals, Inc. +2.04% +12.16%
03-27 Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan MT
03-07 Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Merrimack Pharmaceuticals Insider Bought Shares Worth $627,125, According to a Recent SEC Filing
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Insider Buy: Merrimack Pharmaceuticals
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Insider Buy: Merrimack Pharmaceuticals
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Insider Buy: Merrimack Pharmaceuticals
Insider Buy: Merrimack Pharmaceuticals
Insider Buy: Merrimack Pharmaceuticals
Insider Buy: Merrimack Pharmaceuticals
Merrimack Pharmaceuticals Shares Soar as Partner Ipsen Says Pancreatic Cancer Drug Study Meets Main Endpoint
ETF Preview: ETFs, Stock Futures Down Pre-Bell After Mortgage Applications Report
Merrimack Pharmaceuticals, Inc. Provides Ipsen Report That Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Merrimack Says Ipsen's Phase 3 Trial of Onivyde to Treat Lung Cancer Didn't Meet Primary Endpoint; Merrimack Shares Drop
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MACK Stock
  4. News Merrimack Pharmaceuticals, Inc.
  5. Other languages